JP2015535233A - ガレクチン−３のガラクトシド阻害剤及び肺線維症のためのその使用 - Google Patents

ガレクチン−３のガラクトシド阻害剤及び肺線維症のためのその使用 Download PDF

Info

Publication number
JP2015535233A
JP2015535233A JP2015538502A JP2015538502A JP2015535233A JP 2015535233 A JP2015535233 A JP 2015535233A JP 2015538502 A JP2015538502 A JP 2015538502A JP 2015538502 A JP2015538502 A JP 2015538502A JP 2015535233 A JP2015535233 A JP 2015535233A
Authority
JP
Japan
Prior art keywords
compound
nebulizer
formula
galectin
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015538502A
Other languages
English (en)
Japanese (ja)
Inventor
ニルソン，ウルフ
レフレル，ホーコン
ヘンダーソン，ニール
セシ，タリク
マッキノン，アリソン
Original Assignee
ガレクト・バイオテック・エイビイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA2794066A external-priority patent/CA2794066C/en
Priority claimed from US13/832,672 external-priority patent/US9243021B2/en
Application filed by ガレクト・バイオテック・エイビイ filed Critical ガレクト・バイオテック・エイビイ
Publication of JP2015535233A publication Critical patent/JP2015535233A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/005—Sprayers or atomisers specially adapted for therapeutic purposes using ultrasonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0005—Details of inhalators; Constructional features thereof with means for agitating the medicament
    • A61M15/001—Details of inhalators; Constructional features thereof with means for agitating the medicament using ultrasonic means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0085—Inhalators using ultrasonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2015538502A 2012-10-31 2013-10-30 ガレクチン−３のガラクトシド阻害剤及び肺線維症のためのその使用 Pending JP2015535233A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261720641P 2012-10-31 2012-10-31
CA2794066A CA2794066C (en) 2012-10-31 2012-10-31 Galactoside inhibitor of galectins
CA2794066 2012-10-31
US61/720,641 2012-10-31
CA2795753A CA2795753A1 (en) 2012-10-31 2012-11-15 Novel galactoside inhibitor of galectins
CA2795793 2012-11-15
US13/832,672 US9243021B2 (en) 2012-10-31 2013-03-15 Galactoside inhibitor of galectins
US13/832,672 2013-03-15
PCT/EP2013/072691 WO2014067986A1 (en) 2012-10-31 2013-10-30 Galactoside inhibitor of galectin-3 and its use for treating pulmonary fibrosis

Publications (1)

Publication Number Publication Date
JP2015535233A true JP2015535233A (ja) 2015-12-10

Family

ID=52686686

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015538502A Pending JP2015535233A (ja) 2012-10-31 2013-10-30 ガレクチン−３のガラクトシド阻害剤及び肺線維症のためのその使用

Country Status (7)

Country Link
EP (2) EP3278805A1 (OSRAM)
JP (1) JP2015535233A (OSRAM)
CN (1) CN104755088A (OSRAM)
CA (1) CA2884802A1 (OSRAM)
ES (1) ES2817888T3 (OSRAM)
IN (1) IN2015DN02573A (OSRAM)
WO (1) WO2014067986A1 (OSRAM)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018537469A (ja) * 2015-12-18 2018-12-20 ガレクト・バイオテック・エイビイ 結晶多形とプロセス
JP2021523951A (ja) * 2018-05-17 2021-09-09 アクチュエイト セラピューティクス、インク． グリコーゲンシンターゼキナーゼ３型β阻害剤による特発性肺線維症の治療
JP2021527102A (ja) * 2018-06-15 2021-10-11 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ガレクチン−３抑制剤を模したテトラヒドロピラン系チオ二糖類

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9243021B2 (en) 2012-10-31 2016-01-26 Galecto Biotech Ab Galactoside inhibitor of galectins
EP2620443A1 (en) 2012-01-25 2013-07-31 Galecto Biotech AB Novel galactoside inhibitors of galectins
EP3166956B1 (en) * 2014-07-09 2020-03-18 Galecto Biotech AB Novel hybrid galactoside inhibitor of galectins
ES2776255T3 (es) 2015-01-16 2020-07-29 Galecto Biotech Ab Novedoso inhibidor de galactósido de galectinas
CN113621005B (zh) 2015-01-30 2025-07-04 格莱克特生物技术公司 半乳糖凝集素的α-D-半乳糖苷抑制剂
EP3294293B1 (en) 2015-05-12 2020-11-18 Galecto Biotech AB Once-daily treatment of pulmonary fibrosis
JP6915956B2 (ja) * 2015-05-15 2021-08-11 ガレクト・バイオテック・エイビイ 肺線維症の１日１回の治療
WO2017019770A1 (en) * 2015-07-27 2017-02-02 Wayne State University Compositions and methods relating to galectin detection
CA3000924A1 (en) * 2015-11-09 2017-05-18 Galecto Biotech Ab Novel galactoside inhibitors of galectins
KR102346913B1 (ko) * 2016-03-04 2022-01-04 갈랙틴 사이언시즈, 엘엘씨 갈렉틴과 관련된 질환의 예방 및 치료를 위한 셀레노갈락토시드 화합물 및 이의 용도
WO2018011093A1 (en) 2016-07-12 2018-01-18 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
CN109563119A (zh) * 2016-07-12 2019-04-02 格莱克特生物技术公司 半乳糖凝集素的α-D-半乳糖苷抑制剂
CA3062648A1 (en) * 2017-05-12 2018-11-15 Galectin Sciences, Llc Compounds for the prevention and treatment of diseases and the use thereof
WO2019067702A1 (en) 2017-09-27 2019-04-04 Bristol-Myers Squibb Company INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3
WO2019075045A1 (en) 2017-10-11 2019-04-18 Bristol-Myers Squibb Company INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3
CA3085356A1 (en) 2017-12-29 2019-07-04 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectin and galectin-3
WO2019137971A1 (en) 2018-01-10 2019-07-18 Galecto Biotech Ab Novel galactoside inhibitor of galectins
US20210138080A1 (en) 2018-06-29 2021-05-13 Glykos Biomedical Oy Conjugates
JP2022508720A (ja) 2018-10-15 2022-01-19 ガレクト バイオテック エービー ガレクチンのガラクトシド阻害剤
CN113286632A (zh) 2018-10-15 2021-08-20 格莱克特生物技术公司 半乳糖凝集素的半乳糖苷抑制剂前药
CA3116515A1 (en) 2018-11-21 2020-05-28 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
CN113166122A (zh) 2018-12-06 2021-07-23 百时美施贵宝公司 半乳糖凝集素-3的小分子抑制剂
BR112021012482A2 (pt) 2018-12-27 2021-09-08 Glycomimetics, Inc. C-glicosídeos inibidores de galectina-3
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
WO2020198266A1 (en) 2019-03-26 2020-10-01 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
KR102890853B1 (ko) 2019-04-10 2025-11-24 브리스톨-마이어스 스큅 컴퍼니 갈렉틴-3의 소분자 억제제
WO2020248068A1 (en) 2019-06-14 2020-12-17 UNIVERSITé LAVAL Synthesis of 3-azido-3-deoxy-d-galactopyranose
WO2020260351A1 (en) 2019-06-24 2020-12-30 Galecto Biotech Ab Large scale process of 3,3'-dideoxy-3,3'-bis-[4-(3-fluorophenyl)-1h-1,2,3-triazol-1-yl]-1,1'-sulfanediyl-di-beta-d-galactopyranoside
US12441754B2 (en) 2019-07-03 2025-10-14 Galecto Biotech Ab Galactoside inhibitor of galectins
EP3993872A1 (en) 2019-07-03 2022-05-11 Galecto Biotech AB Novel galactoside inhibitor of galectins
CN114450282A (zh) 2019-07-05 2022-05-06 格莱克特生物技术公司 半乳糖凝集素的新型半乳糖苷抑制剂
CN114206892A (zh) 2019-08-09 2022-03-18 爱杜西亚药品有限公司 (2-乙酰氨基)硫代-β-D-吡喃半乳糖苷衍生物
JP7612662B2 (ja) 2019-08-09 2025-01-14 イドルシア・ファーマシューティカルズ・リミテッド （ヘテロ）アリール－メチル－チオ－ベータ－ｄ－ガラクトピラノシド誘導体
UA128909C2 (uk) 2019-08-15 2024-11-20 Ідорсія Фармасьютікалз Лтд 2-гідроксициклоалкан-1-карбамоїльні похідні
WO2021038068A1 (en) 2019-08-29 2021-03-04 Idorsia Pharmaceuticals Ltd Alpha-d-galactopyranoside derivatives
US20230038373A1 (en) 2019-12-18 2023-02-09 Glykos Biomedical Oy Stabile conjugate
US20230107479A1 (en) * 2020-03-23 2023-04-06 G3 Pharmaceuticals, Inc. Methods and compositions for preventing and treating fibrosis resulting from a coronavirus infection
CA3173316A1 (en) * 2020-03-31 2021-10-07 Galecto Biotech Ab Large scale process for preparing 1,2,4, 6-tetra-0-acetyl-3-azid0-3-de0xy-d-galact0pyran0side
EP4146646A1 (en) 2020-05-05 2023-03-15 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
EP4149939A1 (en) 2020-05-11 2023-03-22 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
CN115768768A (zh) 2020-05-28 2023-03-07 百时美施贵宝公司 半乳凝素-3抑制剂
TWI890869B (zh) 2020-10-06 2025-07-21 瑞士商愛杜西亞製藥有限公司 α-D-吡喃半乳糖苷之螺衍生物
WO2022090544A1 (en) 2020-11-02 2022-05-05 Idorsia Pharmaceuticals Ltd Galectin-3 inhibiting 2-hydroxycycloalkane-1 -carbamoyl derivatives
EP4291556B1 (en) 2021-02-09 2025-04-23 Idorsia Pharmaceuticals Ltd Hydroxyheterocycloalkane-carbamoyl derivatives
IL305581A (en) 2021-03-03 2023-10-01 Idorsia Pharmaceuticals Ltd Triazolyl-methyl-converted alpha-D-galactopyranoside histories
WO2025111704A1 (en) * 2023-12-01 2025-06-05 UNIVERSITé LAVAL Selective inhibitors of galectin-3

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005513031A (ja) * 2001-11-26 2005-05-12 アラクノーバ・セラピューティックス・リミテッド 肺線維症の処置のためのｐｐａｒアクチベーターの使用
WO2006009209A1 (ja) * 2004-07-22 2006-01-26 Kaken Pharmaceutical Co., Ltd. 慢性炎症性肺疾患を予防もしくは治療する薬剤
WO2012142320A2 (en) * 2011-04-12 2012-10-18 Moerae Matrix Inc Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0170715B1 (de) 1984-08-09 1988-04-13 Inge Brugger Zerstäubervorrichtung
US5152456A (en) 1989-12-12 1992-10-06 Bespak, Plc Dispensing apparatus having a perforate outlet member and a vibrating device
GB9027234D0 (en) 1990-12-15 1991-02-06 Harris Pharma Ltd An inhalation device
ES2141108T3 (es) 1991-07-02 2000-03-16 Inhale Inc Metodo y dispositivo para proporcionar medicamentos en aerosol.
WO1997025086A2 (en) 1996-01-03 1997-07-17 Glaxo Group Limited Inhalation device
DE19726110C2 (de) 1997-06-20 1999-07-22 Draegerwerk Ag Aerosolgenerator für Beatmungssysteme
US6962151B1 (en) 1999-11-05 2005-11-08 Pari GmbH Spezialisten für effektive Inhalation Inhalation nebulizer
DE10102846B4 (de) 2001-01-23 2012-04-12 Pari Pharma Gmbh Aerosolgenerator
EP1304130B1 (de) 2001-10-18 2004-06-23 PARI GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung
EP1386672B1 (en) 2002-08-02 2010-04-07 PARI Pharma GmbH Fluid droplet production apparatus
DE10250625A1 (de) 2002-10-30 2004-05-19 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung
DE10257381B4 (de) 2002-12-09 2006-09-14 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung
SE0401301D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
SE0401300D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
EP2424873B1 (en) 2009-04-28 2017-11-15 Galecto Biotech AB Novel galactoside inhibitors of galectins
DE102009026636B4 (de) 2009-06-02 2011-04-14 Pari Pharma Gmbh Verfahren zum Verschweißen einer Membran mit einem Träger bei der Herstellung eines Membranverneblers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005513031A (ja) * 2001-11-26 2005-05-12 アラクノーバ・セラピューティックス・リミテッド 肺線維症の処置のためのｐｐａｒアクチベーターの使用
WO2006009209A1 (ja) * 2004-07-22 2006-01-26 Kaken Pharmaceutical Co., Ltd. 慢性炎症性肺疾患を予防もしくは治療する薬剤
WO2012142320A2 (en) * 2011-04-12 2012-10-18 Moerae Matrix Inc Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDECINE, vol. 185, no. 5, JPN6017029943, March 2012 (2012-03-01), pages 537 - 546, ISSN: 0003755339 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018537469A (ja) * 2015-12-18 2018-12-20 ガレクト・バイオテック・エイビイ 結晶多形とプロセス
JP2021105029A (ja) * 2015-12-18 2021-07-26 ガレクト・バイオテック・エイビイ 結晶多形とプロセス
JP2021191777A (ja) * 2015-12-18 2021-12-16 ガレクト・バイオテック・エイビイ 結晶多形および医薬組成物
JP7254130B2 (ja) 2015-12-18 2023-04-07 ガレクト・バイオテック・エイビイ 結晶多形および医薬組成物
JP2021523951A (ja) * 2018-05-17 2021-09-09 アクチュエイト セラピューティクス、インク． グリコーゲンシンターゼキナーゼ３型β阻害剤による特発性肺線維症の治療
JP7471660B2 (ja) 2018-05-17 2024-04-22 アクチュエイト セラピューティクス インク． グリコーゲンシンターゼキナーゼ３型β阻害剤による特発性肺線維症の治療
JP2024069221A (ja) * 2018-05-17 2024-05-21 アクチュエイト セラピューティクス インク． グリコーゲンシンターゼキナーゼ３型β阻害剤による特発性肺線維症の治療
US12083098B2 (en) 2018-05-17 2024-09-10 Actuate Therapeutics Inc. Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form β inhibitors
JP2021527102A (ja) * 2018-06-15 2021-10-11 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ガレクチン−３抑制剤を模したテトラヒドロピラン系チオ二糖類
JP7190513B2 (ja) 2018-06-15 2022-12-15 ブリストル－マイヤーズ スクイブ カンパニー ガレクチン－３抑制剤を模したテトラヒドロピラン系チオ二糖類

Also Published As

Publication number Publication date
WO2014067986A8 (en) 2016-04-14
CN104755088A (zh) 2015-07-01
WO2014067986A1 (en) 2014-05-08
EP2914269B1 (en) 2020-07-29
EP3278805A1 (en) 2018-02-07
CA2884802A1 (en) 2014-05-08
EP2914269A1 (en) 2015-09-09
ES2817888T3 (es) 2021-04-08
IN2015DN02573A (OSRAM) 2015-09-11

Similar Documents

Publication Publication Date Title
JP2015535233A (ja) ガレクチン−３のガラクトシド阻害剤及び肺線維症のためのその使用
US9580456B2 (en) Galactoside inhibitor of galectin-3 and its use for treating pulmonary fibrosis
US11084828B2 (en) Use of the FL118 core chemical structure platform to generate FL118 derivatives for treatment of human disease
KR101257550B1 (ko) 세포내 칼슘을 조절하는 화합물
RU2693382C2 (ru) Лечение заболевания дыхательной системы
JP7097874B2 (ja) リシルオキシダーゼ様２阻害剤の使用
JP2010539243A (ja) 喘息、肺及び気道の炎症、呼吸器、間質性、肺性および線維性疾患の処置のためのｌｉｇｈｔ阻害剤
WO2011159633A1 (en) Inhalable formulations of lysophosphatdic acid receptor antagonists
US12215095B2 (en) Compounds for the treatment of respiratory diseases
US10258634B2 (en) Ciclesonide for the treatment of airway disease in horses
Milara et al. MUC1 deficiency mediates corticosteroid resistance in chronic obstructive pulmonary disease
WO2021197396A1 (zh) 氘代氧化苯砷化合物及其应用
JP2023134493A (ja) 呼吸器疾患の治療のための化合物
US10220091B2 (en) Combination treatments with sonic hedgehog inhibitors
TW202227078A (zh) 老年及老化患者的病毒性呼吸道感染及失調的免疫反應之治療
US20060148712A1 (en) Monocyte chemoattractant activity of galectin-3
WO2002060535A1 (en) Method of treating inflammatory conditions by inhibiting cytosolic phospholipase a¿2?
CN102460168B (zh) 两种抗sparc抗体用于预测对化学疗法的反应的用途
CA2795753A1 (en) Novel galactoside inhibitor of galectins
US20060276440A1 (en) Treatment of inflammatory disorders
JP5555255B2 (ja) 呼吸器疾患の治療のためのスルホンアミド化合物
CN101005855A (zh) 治疗由ccr2介导的疾病或紊乱的方法
KR20210060642A (ko) 성장 관련 질환 및/또는 그것의 임상적 상태를 억제 및/또는 치료하기 위한 조성물 및 방법
AU2013322342A1 (en) Therapeutic for Treating Inflammatory Lung Disorders
Milara et al. MUC1 deficiency mediates corticosteroid resistance in chronic obstructive pulmonary

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160818

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170815

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180207

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180320